NCT04339062View on ClinicalTrials.gov

Cemiplimab in AlloSCT/SOT Recipients With CSCC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 3, 2020

Primary Completion Date

June 12, 2023

Study Completion Date

March 1, 2025

Conditions
Cutaneous Squamous Cell CarcinomaAdvanced Cancer
Interventions
DRUG

Cemiplimab

Cemiplimab: via IV, flat predetermined dosage every 21 days.

DRUG

Everolimus

Everolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab

DRUG

Sirolimus

Sirolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab

DRUG

Prednisone

40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapered dosing while receiving Cemiplimab

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT04339062 - Cemiplimab in AlloSCT/SOT Recipients With CSCC | Biotech Hunter | Biotech Hunter